|
Originally published In Press as doi:10.1074/jbc.M209700200 on October 25, 2002
J. Biol. Chem., Vol. 277, Issue 51, 49700-49706, December 20, 2002
Orientation-dependent Influence of an Intergenic
Enhancer on the Promoter Activity of the Divergently Transcribed
Mouse Shsp/ B-crystallin and
Mkbp/HspB2 Genes*
Shivalingappa K.
Swamynathan and
Joram
Piatigorsky
From the Laboratory of Molecular and Developmental Biology, NEI,
National Institutes of Health, Bethesda, Maryland 20892
Received for publication, September 20, 2002
 |
ABSTRACT |
The mouse Shsp/ B-crystallin and
Mkbp/HspB2 genes are closely linked and
divergently transcribed. In this study, we have analyzed the
contribution of the intergenic enhancer to
Shsp/ B-crystallin and Mkbp/HspB2
promoter activity using dual-reporter vectors in transient transfection
and transgenic mouse experiments. Deletion of the enhancer reduced
Shsp/ B-crystallin promoter activity by 30- and 93-fold
and Mkbp/HspB2 promoter activity by 6- and
10-fold in transiently transfected mouse lens -TN4 and myoblast
C2C12 cells, respectively. Surprisingly, inversion of the enhancer
reduced Shsp/ B-crystallin promoter activity by 17-fold,
but did not affect Mkbp/HspB2 promoter activity
in the transfected cells. In contrast, enhancer activity was
orientation-independent in combination with a heterologous promoter in
transfected cells. Transgenic mouse experiments established the
orientation dependence and Shsp/ B-crystallin promoter
preference of the intergenic enhancer in its native context. The
orientation dependence and preferential effect of the
Shsp/ B-crystallin enhancer on the
Shsp/ B-crystallin promoter provide an example of
adaptive changes in gene regulation accompanying the functional diversification of duplicated genes during evolution.
 |
INTRODUCTION |
Crystallins are abundant, water-soluble, cytoplasmic proteins
responsible for the transparent and refractive properties of the lens.
In vertebrates, the -, -, and -crystallins are the most
common. -Crystallin is an aggregate of two polypeptides, A and
B, both of which are members of the SHSP (small
heat shock protein) family of
molecular chaperones, sharing 55% identity in their amino acid
sequences. Expression of crystallins is abundant in, but not restricted
to, the lens. Most, if not all, crystallins found in exceedingly high
concentrations in the lens are also expressed in diverse tissues in
variable amounts, where they serve as metabolic enzymes or stress
proteins. This exploitation of different properties of a single
polypeptide via differential gene regulation in different tissues has
been termed "gene sharing" (1-3).
Shsp/ B-crystallin promoter activity (4) and accumulation
of the Shsp/ B-crystallin transcripts (5) begin in the
developing lens placode as early as day 9.5 of embryonic development.
Outside of the lens, Shsp/ B-crystallin is expressed at
considerable levels in the heart and skeletal muscle and at low levels
in several other tissues (4-8). In addition,
Shsp/ B-crystallin is stress-inducible (9), and its
overexpression has been documented in various diseases (10-13).
Previous work from our laboratory demonstrated that the 164/+44 bp
promoter of the Shsp/ B-crystallin gene is sufficient to
direct the expression of a reporter gene in the lens and that the
cis-acting lens-specific regulatory regions 1 ( 147/ 118
bp) and 2 ( 78/ 46 bp) bound by both Pax-6 and retinoic acid/retinoid
receptors are used for this tissue-specific activity (14-17). An
upstream enhancer ( 426/ 258 bp) containing at least five
cis-elements can activate the herpes simplex virus thymidine kinase promoter in transfection experiments, independent of the position and orientation of the enhancer in the plasmid (18-20).
The Mkbp/HspB2 (myotonic dystrophy
protein kinase-binding
protein/heat shock
protein B2) gene, another member of the
Shsp/ -crystallin family, is divergently transcribed from
863 bp relative to the transcription start site of the
Shsp/ B-crystallin gene in the mouse (see Fig.
1A) (21, 22). Expression of Mkbp/HspB2
is detectable in the heart and skeletal muscle (22). Unlike
Shsp/ B-crystallin, Mkbp/HspB2 is
not expressed in the lens and is not stress-inducible (22). Studies in
mice in which both the Shsp/ B-crystallin and Mkbp/HspB2 genes have been disrupted by
homologous recombination demonstrated that these two genes are not
essential for normal development of a transparent lens, but one or both
are required to maintain the integrity of skeletal muscle cells
(23).
Bidirectional gene organization described above for
Mkbp/HspB2 and Shsp/ B-crystallin is
a common feature in eukaryotes (24). Divergent transcription of genes
with differential expression profiles, such as the
Shsp/ B-crystallin and Mkbp/HspB2
genes, results in conflicting demands on intergenic enhancers. In this study, bidirectional, dual-reporter genes were used to test the effect
of deleting or inverting the intergenic enhancer on
Shsp/ B-crystallin and Mkbp/HspB2
promoter activity in transfected cells and transgenic mice. Our results
demonstrate that this intergenic enhancer preferentially activates the
Shsp/ B-crystallin promoter, although it has some effect
on the Mkbp/HspB2 promoter as well. Furthermore,
we show that the effect of the enhancer on
Shsp/ B-crystallin promoter activity is
orientation-dependent in its native context. Our results thus
reveal a functional specialization of this intergenic enhancer associated with the duplication and subsequent evolution of these linked Shsp-related genes arranged in a head-to-head manner.
 |
EXPERIMENTAL PROCEDURES |
Isolation of Total RNA and
RT1-PCR--
Total RNA was
isolated from 30 mg of tissues using an RNeasy mini kit (QIAGEN Inc.,
Valencia, CA). Eluted RNA was quantified by measuring absorbance at 260 nm, and the concentration was adjusted with RNase-free water to 100 ng/µl. One-step RT-PCR was done using Ready-To-Go RT-PCR beads
(Amersham Biosciences). 500 ng of total RNA was used to amplify the
280-bp fragment from Mkbp/HspB2 with primers 8777 (complementary nucleotides +945 to +924 in exon 2 of the
Mkbp/HspB2 gene, ATAGAGCAGCTCGAACCCGCCA) and 8778 (nucleotides +665 to +684 in exon 2 of the
Mkbp/HspB2 gene, CTCTATCACGGCTACTATGT), whereas
50 ng of total RNA was used to amplify the 262-bp fragment from the
Shsp/ B-crystallin gene with primers 8779 (nucleotides +3744 to +3763 in exon 3 of the Shsp/ B-crystallin
gene, GAACATGGCTTCATCTCCAG) and 8780 (complementary nucleotides +4025
to +4006 in exon 3 of the Shsp/ B-crystallin gene,
AGCTTCAGCACTAGTCACAG). The RT-PCR products were separated on a 1.5%
agarose gel using Tris borate/EDTA.
Construction of the Reporter Vectors--
Unless otherwise
stated, all nucleotide positions used here are relative to the
transcription start site of the Shsp/ B-crystallin gene.
The 2.0-kb fragment containing the firefly luciferase gene was excised
from the plasmid pGL3-Basic (Promega, Madison, WI) with SmaI
and SalI and cloned into the pRL-Null vector (Promega) linearized with SmaI and SalI to generate the
vector pRLFL-Null. The 959/+42 bp fragment between the mouse
Shsp/ B-crystallin and Mkbp/HspB2
genes, including both genes' transcription start sites, but not their
translation start sites, was amplified using primers 8703 ( 959GACTGCTGTTGCGACTAGTAGC 938) and 8704 (+42GGCTAGATGAATGCAGAGTC+23), purified,
and ligated into the pRLFL-Null vector linearized with SmaI.
Clones with both orientations of the intergenic region were isolated
and labeled as pFL-HSPB2 B-RL and pRL-HSPB2 B-FL (where RL
is Renilla luciferase and FL is firefly luciferase).
Recombinant PCR-mediated ligation (25) was used to delete or invert the
436/ 258 bp enhancer. For deletion, the fragment upstream of the
enhancer was amplified using primers 8703 and 8844 ( 453GAACTAGGTGTCTGACTG 256), and the
fragment downstream of the enhancer was amplified using primers 8704 and 8912 ( 453CAGTCAGACACCTAGTTC 436 joined
to 256ACAAGGATGGGGTGGGTG 239), the
5'-half of which is complementary to primer 8844. These two fragments
were then ligated by PCR using primers 8703 and 8704 to amplify the
959/+42 bp fragment with a targeted deletion of the 436/ 258 bp
enhancer. The fragment so produced was cloned into the SmaI
site of the pRLFL-Null vector described above, and the resultant
plasmid was labeled as pFL-HSPB2DelE B-RL.
For inverting the 436/ 258 bp enhancer, the intergenic region was
initially amplified in three different fragments: fragment 1, 959 to
436 bp upstream of the enhancer using primers 8703 and 8844; fragment
2, 258 to +42 bp downstream of the enhancer using primers 8704 and
8847 ( 419GAGTCCTAGAGGAGAGC 435 joined
to 257AACAAGGATGGGGTGGGTG 239); and
fragment 3, the 436/ 258 bp enhancer using primer 8845 ( 436TGCTCTCCTCTAGGACTC 419), complementary
to the 5'-half of primers 8847 and 8846 ( 453CAGTCAGACACCTAGTTC 436 joined to
257TCTCTGGAGCTAGGATGG 274), the
5'-half of which is complementary to primer 8844. In the next step,
fragment 3 was ligated in the inverted orientation by recombinant PCR
with (a) the upstream fragment using primers 8703 and 8845 or (b) the downstream fragment using primers 8846 and 8704. These reactions generated two different fragments, upstream fragment 4 and downstream fragment 5, each with the enhancer attached in the
inverted orientation. In the final step, fragments 4 and 5 were ligated
by recombinant PCR using primers 8703 and 8704. The final PCR product
containing the inverted enhancer was cloned into the pRLFL-Null plasmid
linearized with SmaI, and the resultant plasmid was labeled
pFL-HSPB2InvE B-RL. The intergenic region in all these plasmids was
sequenced using ABI Big Dye terminator mixture and an ABI Prism 310 genetic analyzer to confirm the intended deletion or the inversion of
the enhancer.
The vector pRL-HSPB2 B-FL described above was used as the starting
material for generating the vectors 820RL, 672RL, 533RL, 220RL,
190RL, and 163RL. pRL-HSPB2 B-FL was digested with the following enzymes, and the resulting large fragment was religated to
generate the corresponding vectors: HindIII for 820RL,
AgeI and HindIII for 672RL, SphI for
533RL, SpeI for 220RL, SacI for 190RL, and
PvuII and HindIII for 163RL.
The vectors pGL3-PE-3 and pGL3-PE-4 were constructed as follows. The
450/ 249 bp fragment was amplified using primers 9829 (nucleotides
267 to 249 with a BglII site,
ATGCAGATCTATCCTTGTTCTCTGGAGCT) and 9830 (nucleotides 450 to 430
with a BglII site, ATGCAGATCTCAGACACCTAGTTCTGCTCT), digested
with BglII, and cloned into the BglII site of the
base vector pGL3-Promoter (Promega). Orientation of the enhancer in these clones was tested with StyI digestion, and clones
containing the enhancer in different orientations were labeled
pGL3-PE-3 and pGL3-PE-4.
Cell Culture, Transfections, and Dual-luciferase
Assays--
Mouse lens epithelial -TN4 cells (26), rabbit lens
epithelial N/N1003 cells (27), and mouse myoblast C2C12 cells (28) were
propagated in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum and 50 µg/ml of gentamycin in 5%
CO2. Cells in six-well plates in the mid-log phase of
growth were transfected with 1 µg of different plasmids using 3 µl
of FuGENE 6 (Roche Molecular Biochemicals). After 2 days, cells were washed with cold phosphate-buffered saline and lysed with 500 µl of
passive lysis buffer (Promega). The lysate was clarified, and 100 µg
of lysate was analyzed using a Renilla luciferase assay or
dual-luciferase assay kit (Promega) and a Tropix TR717 microplate luminometer (Applied Biosystems). The measurement was integrated over
10 s with a delay of 2 s. When pCMV-gal was used to normalize the transfection efficiency across the different treatments,
-galactosidase assays were performed as described (29), and the
normalized amount of lysate was then used in dual-luciferase assays.
Generation of DNA Fragments for Production of Transgenic
Mice--
Plasmids pFL-HSPB2 B-RL, pRL-HSPB2 B-FL, and
pFL-HSPB2DelE B-RL or pFL-HSPB2InvE B-RL were digested with
BamHI to release the fragment containing the firefly and
Renilla luciferase genes under the control of the intergenic
region. These fragments were eluted from agarose gels using Geneclean
II (BIO 101, Inc., Vista, CA) and purified further by chloroform
extraction and ethanol precipitation. The purified fragments were used
to generate the transgenic mice at the NEI Transgenic Mouse Facility as
described previously (30). Genomic DNA from founder mice was isolated and assayed for the presence of the transgenes by PCR using
transgene-specific primers. Founders positive for the transgene were
mated with wild-type FVB/N mice to obtain F1 offspring.
Analysis of Transgenic Mice--
All analyses with the
transgenic mice were done with ~8-week-old mice. About 100 mg of each
tissue analyzed was homogenized in 500 µl of ice-cold 1× passive
lysis buffer on ice using a hand-held Kontes homogenizer for ~30-45
s. The lysate was cleared by centrifugation at 12,000 rpm for 15 min at
4 °C. Protein concentration in the supernatant fractions was
estimated using the bicinchoninic acid method (Pierce). Lysates were
diluted to achieve equal concentration, and 50 µg of protein from
each tissue was subjected to dual-luciferase assays as described above.
For the DB28 series of transgenic mice (4), 50 µg of protein from
different tissues was subjected to -galactosidase assays using
chlorophenol red -D-galactopyranoside (Roche Molecular
Biochemicals) as substrate (29).
 |
RESULTS |
Relative Levels of Expression of Mouse
Shsp/ B-crystallin and Mkbp/HspB2
Genes--
Organization of the
Mkbp/HspB2-Shsp/ B-crystallin locus
is shown in Fig. 1A. To detect
the relative levels of expression of the
Shsp/ B-crystallin and Mkbp/HspB2
genes in various tissues of the adult mouse, semiquantitative RT-PCR
was performed with 50 ng (for Shsp/ B-crystallin) or 500 ng (for Mkbp/HspB2) of total RNA isolated from
different tissues of an 8-week-old mouse. The resulting products were
separated on a 1.5% agarose gel (Fig. 1B). Expression of
the Shsp/ B-crystallin gene was most abundant in the lens,
followed by the heart, muscle, diaphragm, lung, and cornea. In
contrast, the Mkbp/HspB2 transcripts could be
detected at a low level only in the heart, muscle, and diaphragm (Fig. 1B). The trace amounts of DNA seen in the lens and lung
lanes migrated below that of Mkbp/HspB2 and are
an artifact of this procedure.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
Organization and relative levels of
expression of the mouse
Shsp/ B-crystallin and
Mkbp/HspB2 genes. A,
schematic showing the organization of the
Mkbp/HspB2-Shsp/ B-crystallin locus
is presented above. Although the effect of the intergenic enhancer on
Shsp/ B-crystallin promoter activity is well known, its
effect on Mkbp/HspB2 promoter activity is not.
The major question addressed in this study, viz. the effect
of inverting the enhancer within its natural location on the relative
activities of the two promoters, is depicted below. DPE,
downstream promoter element; LSR, lens-specific
regulatory region; TATA, TATA box. B,
semiquantitative RT-PCR analysis of relative levels of expression of
Shsp/ B-crystallin and Mkbp/HspB2.
RT-PCR products separated on a 1.5% agarose gel are shown.
|
|
Deletion Analysis of the Effect of the Enhancer on the
Mkbp/HspB2 Promoter--
To identify the role of the
enhancer in the regulation of Mkbp/HspB2 promoter
activity, we constructed a series of reporter vectors wherein the
Renilla luciferase gene was under the control of
progressively deleted Mkbp/HspB2 promoter
fragments. Murine myoblast C2C12 cells, which are known to support
Mkbp/HspB2 gene expression, were used for these
transfections (22). Deletion of the sequence between 672 and 533 bp
relative to the transcription start site of the
Mkbp/HspB2 gene reduced
Mkbp/HspB2 promoter activity by slightly <50%
(Fig. 2). Further deletion to 163 bp had no effect on promoter activity. In the 533RL construct, the element B-E3 (containing putative binding sites for
CAAT/enhancer-binding protein and/or Sp1) and the myogenic
response factor binding site (known to bind muscle-enriched
transcription factors MyoD, myogenin, and/or Myf-1) were deleted (20).
These results suggest that the minimum promoter elements supporting the
expression of the Mkbp/HspB2 promoter in C2C12
cells are located within 163 bp of its transcription start site. In
addition, the 436/ 257 bp enhancer mediates only a 2-fold activation
of the Mkbp/HspB2 promoter, in contrast to the
>30-fold activation of the Shsp/ B-crystallin promoter
observed earlier in C2C12 cells (18, 19).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Deletion analysis of the effect of the
enhancer on Mkbp/HspB2 promoter
activity. Organization of the
Shsp/ B-crystallin and Mkbp/HspB2
intergenic region is shown at the top. Individual elements within the
enhancer are shown in greater detail. Nucleotide positions without
parentheses are relative to the +1 transcription start site
of the Mkbp/HspB2 gene; numbers shown
in parentheses are relative to the
Shsp/ B-crystallin transcription start site. Transient
transfection assays were done in C2C12 cells with reporter vectors
containing the Renilla luciferase gene under the control of
the various progressively deleted fragments of the
Mkbp/HspB2 promoter shown on the left. The
results of Renilla luciferase assays are shown in the
bar graph on the right for each of the vectors tested.
HSE, heat shock response element; MRF, myogenic
response factor binding site; RLU, relative luciferase
units.
|
|
Transient Transfection Assays with Bidirectional Dual-reporter
Vectors--
We next investigated whether inverting the enhancer will
change the relative activities of the Mkbp/HspB2
and Shsp/ B-crystallin promoters. Plasmids containing
bidirectional dual-reporter genes under the control of the intergenic
region were tested by transient transfection in mouse lens epithelial
-TN4 and myoblast C2C12 cells (Fig.
3A). The
Shsp/ B-crystallin promoter activity was 10-fold higher in
the transfected myoblast C2C12 cells than in the transfected lens
epithelial -TN4 cells (Fig. 3, compare B and
D). The Shsp/ B-crystallin promoter was 25 and
32 times more active than the Mkbp/HspB2 promoter
in the -TN4 and C2C12 cells, respectively. Deletion of the
436/ 258 bp enhancer reduced Shsp/ B-crystallin promoter activity to ~1 and 3% and Mkbp/HspB2
promoter activity to ~10 and 16% of the corresponding activity
observed with a plasmid containing the properly oriented enhancer in
transfected C2C12 and -TN4 cells, respectively (Fig. 3, C
and E). When the enhancer was inverted,
Shsp/ B-crystallin promoter activity decreased to ~6%
and Mkbp/HspB2 promoter activity decreased to
~80% of the corresponding activity observed with the plasmid
containing the properly oriented enhancer in transfected C2C12 and
-TN4 cells (Fig. 3, C and E). These results
indicate that the intergenic enhancer shows orientation dependence and
preference for the Shsp/ B-crystallin promoter.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
Transient transfection assays with
bidirectional dual-reporter vectors. A, schematic
showing the structures of the dual-reporter vectors used.
Null is an empty vector containing divergently positioned
firefly luciferase (FL) and Renilla luciferase
(RL) genes separated by a SmaI site. The
intergenic region between the Shsp/ B-crystallin and
Mkbp/HspB2 genes was cloned into the
SmaI site in the reporter vectors. Wild Type,
Del E, and Inv E refer to reporter vectors
containing a properly oriented, deleted, or inverted 436/ 257 bp
enhancer, respectively. Firefly and Renilla luciferase
reporter gene activities are shown as relative light units
(RLU)/µg of protein assayed in B (mouse
myoblast C2C12 cells) and D (mouse lens epithelial -TN4
cells). The values obtained with the null, deleted, and inverted
enhancer constructs are presented as percent of the wild type for each
promoter in C (C2C12 cells) and E ( -TN4
cells).
|
|
Analysis of Transgenic Mice Containing Transgenes with the Properly
Oriented, Deleted, or Inverted Enhancer--
Equal amounts of protein
from different tissues of three lines of pFL-HSPB2 B-RL transgenic
mice at 8 weeks of age were analyzed by dual-luciferase assays. The
results are shown in Fig. 4. Significant reporter gene activity driven by the Shsp/ B-crystallin
promoter occurred in the heart, skeletal muscle, diaphragm, and lens
(Fig. 4A). Surprisingly, the lens showed 2-6-fold less
activity compared with different muscle-related tissues (Fig.
4A), despite that the endogenous
Shsp/ B-crystallin transcripts were more abundant in the
lens than in the muscle, heart, or diaphragm (Fig. 1B) (7).
The activity of the Mkbp/HspB2 promoter was
greatest in the heart, followed by the diaphragm and skeletal muscle.
All other tissues tested showed near-background levels of activity for
both the Shsp/ B-crystallin and
Mkbp/HspB2 promoters (data not shown). Similar
results were obtained with pRL-HSPB2 B-FL transgenic mice (data not
shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of deletion or inversion of the
enhancer on Shsp/ B-crystallin
and Mkbp/HspB2 promoter activity in
transgenic mice. A, average activity of firefly
luciferase (FL) and Renilla luciferase
(RL) reporter proteins in extracts from different tissues of
three lines of 8-week-old transgenic mice generated with
pFL-HSPB2 B-RL (wild-type (WT)), pFL-HSPB2DelE B-RL
(Del), or pFL-HSPB2InvE B-RL (Inv, Inv
E) constructs (expressed as relative luciferase units
(RLU)/µg of protein assayed on a logarithmic scale).
B, the ratio of Shsp/ B-crystallin to
Mkbp/HspB2 promoter activity in different tissues
of the transgenic mice generated with the three different constructs
analyzed. Note the use of a logarithmic scale in the y axis
in both A and B.
|
|
In adult pFL-HSPB2DelE B-RL transgenic mice,
Shsp/ B-crystallin promoter activity was <1% in the
heart, skeletal muscle, and diaphragm and ~25% in the lens of the
activity observed in the corresponding tissues of adult
pFL-HSPB2 B-RL transgenic mice (Fig. 4A).
Mkbp/HspB2 promoter activity in
pFL-HSPB2DelE B-RL transgenic mice decreased to ~1% of the
activity observed in the muscle, heart, and diaphragm of
pFL-HSPB2 B-RL transgenic mice, indicating that the
Shsp/ B-crystallin enhancer influences
Mkbp/HspB2 promoter activity also (Fig.
4A).
In adult pFL-HSPB2InvE B-RL transgenic mice,
Shsp/ B-crystallin promoter activity decreased to ~5%
in the lens, 4% in the heart, 3% in the skeletal muscle, and 27% in
the diaphragm of that in the corresponding tissues of pFL-HSPB2 B-RL
transgenic mice (Fig. 4A). Therefore, even though the
inversion of the enhancer within its native context reduced
Shsp/ B-crystallin promoter activity, it did not
completely eliminate the positive effects of the enhancer on the
Shsp/ B-crystallin promoter. Inversion of the intergenic
enhancer led to a 3-fold increase in Mkbp/HspB2 promoter activity in the muscle, but there was no increase in any of
the other tissues tested. Instead, Mkbp/HspB2
promoter activity in pFL-HSPB2InvE B-RL transgenic mice was
reduced to ~50% in the heart and diaphragm compared with the levels
detected in pFL-HSPB2 B-RL transgenic mice (Fig. 4A).
The ratio of Shsp/ B-crystallin to
Mkbp/HspB2 promoter activity should remain the
same in transgenic mice generated with a properly oriented, deleted, or
inverted enhancer if the influence of the intergenic enhancer on the
activity of these two promoters is comparable. However, a sharp
reduction in the
Shsp/ B-crystallin:Mkbp/HspB2 promoter activity ratio, ranging from 20- to 50-fold depending on the
tissue, was observed in the lens, heart, diaphragm, and skeletal muscle
of transgenic mice containing transgenes with either a deleted or
inverted enhancer compared with mice containing a transgene with a
properly oriented enhancer (Fig. 4B). Therefore, even though
the intergenic enhancer activated both the
Mkbp/HspB2 and Shsp/ B-crystallin
promoters, its influence on the latter was 20-50-fold higher in
different tissues.
The 2-6-fold lower activity of the Shsp/ B-crystallin
promoter in the lens than in the heart, diaphragm, and skeletal muscle of the transgenic mice (Fig. 4) was unexpected. However, similar results have been obtained earlier in eight lines of transgenic mice
generated with a construct in which the 919/+44 bp fragment was
driving the expression of the -galactosidase reporter
gene.2 To test whether the
inclusion of upstream sequences increases Shsp/ B-crystallin promoter activity in the lens, we
re-examined pJH21 mice, which have a 4.0 kb/+44 bp
Shsp/ B-crystallin fragment driving the
-galactosidase reporter transgene (4). Quantitative analysis of
-galactosidase expression in different tissues of 8-week-old
transgenic mice showed that Shsp/ B-crystallin promoter activity was, on average, 2-fold less in the lens than in the heart
(data not shown). Thus, the greater activity of the
Shsp/ B-crystallin promoter/enhancer in the heart than in
the lens of our transgenic mice is not due to the absence of sequences
as far as 4.0 kb upstream of the Shsp/ B-crystallin
gene, which includes the intergenic spacer and the
Mkbp/HspB2 gene.
Transient Transfection Assays with the
Shsp/ B-crystallin Enhancer Coupled to a Heterologous
Promoter in Two Different Orientations--
The
orientation-dependent nature of the 436/ 257 bp enhancer
demonstrated here differs from our earlier finding, where it enhanced
the herpes simplex virus thymidine kinase promoter activity in a
position- and orientation-independent manner in transfected cells (18).
Considering this, we tested the orientation dependence of the enhancer
in combination with a different heterologous promoter. The 450/ 249
bp fragment was cloned in both orientations upstream of the SV40
promoter in the pGL3-Promoter vector and transfected into C2C12 and
rabbit lens epithelial N/N1003 cells. The 450/ 249 bp enhancer
up-regulated the transcription from the SV40 promoter by ~6-9-fold,
regardless of the orientation in which it was cloned (Fig.
5, B and C).
Clearly, this enhancer can act in an orientation-independent manner
when fused to a heterologous promoter. Thus, even though this fragment
meets the established criteria for an enhancer in combination with two
different heterologous promoters, it does not do so in its native
context.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 5.
Transfection tests of the
Shsp/ B-crystallin enhancer
fused to a heterologous promoter. A, schematic showing
the structures of different constructs used for transient transfections
in C2C12 and N/N1003 cells. The 450/ 249 bp enhancer was coupled
with the SV40 promoter in these plasmids. B and
C, transient transfection assays with pGL3-Promoter,
pGL3-PE-3, and pGL3-PE-4 in C2C12 and N/N1003 cells. The enhancer
stimulated SV40 promoter activity by ~6-9-fold in an
orientation-independent manner in these cells. RLU, relative
luciferase units.
|
|
 |
DISCUSSION |
Divergent transcription of closely linked genes within related
gene clusters is a recurring theme in eukaryotes (24, 31-35). Often in
these situations, intergenic regulatory elements are shared. In this
study, we have analyzed the contribution of an intergenic enhancer to
divergent transcription of the closely linked
Shsp/ B-crystallin and Mkbp/HspB2
genes. Our results demonstrate that the 436/ 257 bp enhancer is
orientation-dependent in its influence on the
Shsp/ B-crystallin promoter in its native context (Figs. 3
and 4), despite the fact that it works in an orientation-independent manner with heterologous promoters (Fig. 5) (18). Furthermore, we have
shown that even though the enhancer activated both the Mkbp/HspB2 and Shsp/ B-crystallin
promoters, it preferentially stimulated the latter by 20-50-fold in
the heart, skeletal muscle, and lens of the transgenic mice. This
suggests that the intergenic enhancer has evolved different promoter
specificities associated with the functional diversification of the
duplicated Mkbp/HspB2 and
Shsp/ B-crystallin genes.
Many studies on enhancers have employed transient transfection assays
in cultured cells with circular plasmids, where orientation preference
would be obscured by the ability of the enhancer to function either
upstream or downstream of the promoter. This is overcome by the use of
transgenic mice or by inserting insulators in the plasmids used to test
the orientation dependence of different enhancers (36-43). The phrase
"enhancing region" was proposed for an
orientation-dependent DNA stimulatory sequence to reflect
its properties and to distinguish it from orientation-independent enhancers (41). The orientation-dependent nature of the
Shsp/ B-crystallin enhancer we have discovered here places
this intergenic enhancer in the category of enhancing regions
rather than the more general category of enhancers.
Enhancers in the vicinity of multiple promoters can selectively
activate a single promoter (44-48). Several mechanisms have been
proposed to explain preferential interaction between an enhancer and a
specific promoter. First, a difference in the strength or type of a
given promoter can result in preferential up-regulation (44, 49-52).
One possibly relevant difference between the two promoters studied here
is that the Shsp/ B-crystallin promoter contains a well
conserved TATA box, whereas the Mkbp/HspB2
promoter lacks a TATA box, but contains a downstream promoter element
(Fig. 1, DPE). A second possible mechanism involves
insulators (53, 54). The 850/ 660 bp sequence is replete with
GC-rich stretches, likely recognition sites for CCCTC binding
factor CTCF, the 11-zinc finger protein critical for
vertebrate insulators to function (55). Indeed, our current experiments
indicate that there is an insulator between the
Shsp/ B-crystallin enhancer and the
Mkbp/HspB2 promoter, contributing to the
preferential influence of the enhancer on the
Shsp/ B-crystallin
promoter.3 However, this
insulator is not sufficient to explain the orientation dependence of
the Shsp/ B-crystallin enhancer in its native context. It
is possible that one or more discrete cis-regulatory
elements within the enhancer confer orientation dependence in its
native context.
Unexpectedly, the Shsp/ B-crystallin promoter was
3-4-fold less active in the lens compared with the muscle and heart in
the transgenic mice (Fig. 4). Similarly,
Shsp/ B-crystallin promoter activity was ~10-fold less
in transfected lens -TN4 cells than in transfected myoblast C2C12
cells (Fig. 3). A comparison of the relative activity of the
Shsp/ B-crystallin promoter in the lens and muscle of
different transgenic mice taken from the present unpublished2 and published (4, 16-18, 56) studies
demonstrates a shift in Shsp/ B-crystallin promoter
activity from the lens-favored to the muscle-favored mode when the
length of the upstream regulatory sequences increases from 660 to
919 bp (Fig. 6). In view of this shift,
we propose that there is a lens-specific negative regulatory element
within the 919/ 660 bp fragment (Fig. 6). It is also possible that
elements within the coding sequences, introns, or downstream region of
the gene counteract the influence of the lens-specific negative
regulatory element in the endogenous gene, enabling its high level
expression in the lens. Numerous reports have demonstrated the presence
of intronic enhancers in crystallins as well as other genes (38,
57-61).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
Is there a lens-specific negative regulatory
element at 919/ 660
bp? In transgenic mice generated with reporter constructs
controlled by Shsp/ B-crystallin promoter fragments longer
than 919/+44 bp, the activity of the Shsp/ B-crystallin
promoter was relatively higher in the muscle-related tissues than in
the lens. In contrast, in transgenic mice generated with
Shsp/ B-crystallin promoter fragments shorter than or
equal to 660/+44 bp, there was a lens-favored pattern of expression.
We propose that there is a lens-specific negative regulatory element
(NRE) within the 919/ 660 bp fragment of the
Shsp/ B-crystallin upstream regulatory sequences.
FL, firefly luciferase; RL, Renilla
luciferase; LacZ, -galactosidase; CAT,
chloramphenicol acetyltransferase.
|
|
An alternative explanation for the relatively lower expression of the
reporter genes in the lens compared with the heart or muscle may be
found in the biology of the lens. In the adult lens, only the
epithelial cells and a few cells in the equatorial region continue to
be transcriptionally active. In contrast, in the adult heart and
skeletal muscle, most of the cells are transcriptionally active. Thus,
it is possible that Shsp/ B-crystallin promoter activity
appears lower in the lens than in the heart or skeletal muscle when
considering the entire tissue; however, when calculated per cell,
Shsp/ B-crystallin promoter activity may be higher in the
lens epithelial cells than in the heart or muscle in the adult mouse.
The greater number of Shsp/ B-crystallin transcripts in the lens than in the heart, skeletal muscle, or diaphragm (Fig. 1B) may be due in part to mRNA stability and thus is not
inconsistent with the present results on promoter activity. Finally,
SHSP/ B-crystallin protein may be more stable in the lens than the
reporter proteins, possibly adding to the apparent contradiction
between promoter activity and crystallin accumulation in the lens.
Duplicated genes provide the requisite raw material for evolution.
Functional diversification of the duplicated genes often results in new
demands on their expression patterns. In mammals, there are nine known
members of the SHSP family, thought to have originated from a
common ancestor (62). A phylogenetic tree based on the sequence
similarity of the -crystallin domain places MKBP/HSPB2 away from the
cluster of HSP20 and A- and B-crystallins, all found in the lens
at variable amounts, and closer to HSP27, expressed in the muscle (63).
The fact that Mkbp/HspB2 was not recruited for
lens expression, despite its physical proximity to the
Shsp/ B-crystallin gene, reflects the stringent selective pressures operating on the regulation of duplicated genes. In conclusion, the orientation dependence and preferential effect of the
Shsp/ B-crystallin enhancer on the
Shsp/ B-crystallin promoter demonstrated in this study
provide an example of adaptive changes in gene regulation accompanying
the functional diversification of duplicated genes during evolution.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Eric F. Wawrousek, R. Steven
Lee, and Carl Haugen (NEI Transgenic Mouse Facility) for help with
generating and maintaining the transgenic mice used in this study. We
thank Drs. Zbynek Kozmik, David Nees, R. Barry Hough, Jyotshnabala
Kanungo, Janine Davis, Zheng-Ping Xu, and Zdenek Kostrouch and Barbara Norman for useful discussions and help during the course of this work
and constructive criticisms on this paper. We also acknowledge the
extensive unpublished transgenic mouse experiments conducted by Dr.
Elizabeth D. Kaplan referenced in Fig. 6.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Laboratory of
Molecular and Developmental Biology, NEI, NIH, Bldg. 6, Rm. 201, 6 Center Dr., Bethesda, MD 20892. Tel.: 301-496-9467; Fax: 301-402-0781; E-mail: joramp@nei.nih.gov.
Published, JBC Papers in Press, October 25, 2002, DOI 10.1074/jbc.M209700200
2
E. Kaplan and J. Piatigorsky, unpublished data.
3
S. K. Swamynathan and J. Piatigorsky,
manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviation used is:
RT, reverse
transcription.
 |
REFERENCES |
| 1.
|
Piatigorsky, J.,
O'Brien, W. E.,
Norman, B. L.,
Kalumuck, K.,
Wistow, G. J.,
Borras, T.,
Nickerson, J. M.,
and Wawrousek, E. F.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
3479-3483[Abstract/Free Full Text]
|
| 2.
|
Piatigorsky, J.,
and Wistow, G. J.
(1989)
Cell
57,
197-199[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Piatigorsky, J.
(1998)
Prog. Retin. Eye Res.
17,
145-174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Haynes, J. I.,
Duncan, M. K.,
and Piatigorsky, J.
(1996)
Dev. Dyn.
207,
75-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Robinson, M. L.,
and Overbeek, P. A.
(1996)
Investig. Ophthalmol. Vis. Sci.
37,
2276-2284[Abstract/Free Full Text]
|
| 6.
|
Bhat, S. P.,
and Nagineni, C. N.
(1989)
Biochem. Biophys. Res. Commun.
158,
319-325[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Dubin, R. A.,
Wawrousek, E. F.,
and Piatigorsky, J.
(1989)
Mol. Cell. Biol.
9,
1083-1091[Abstract/Free Full Text]
|
| 8.
|
Iwaki, T.,
Kume-Iwaki, A.,
and Goldman, J. E.
(1990)
J. Histochem. Cytochem.
38,
31-39[Abstract]
|
| 9.
|
Klemenz, R.,
Frohli, E.,
Steiger, R. H.,
Schafer, R.,
and Aoyama, A.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3652-3656[Abstract/Free Full Text]
|
| 10.
|
Vicart, P.,
Caron, A.,
Guicheney, P., Li, Z.,
Prevost, M. C.,
Faure, A.,
Chateau, D.,
Chapon, F.,
Tome, F.,
Dupret, J. M.,
Paulin, D.,
and Fardeau, M.
(1998)
Nat. Genet.
20,
92-95[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Iwaki, T.,
Kume-Iwaki, A.,
Liem, R. K.,
and Goldman, J. E.
(1989)
Cell
57,
71-78[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Duguid, J. R.,
Rohwer, R. G.,
and Seed, B.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5738-5742[Abstract/Free Full Text]
|
| 13.
|
van Noort, J. M.,
van Sechel, A. C.,
Bajramovic, J. J.,
el Ouagmiri, M.,
Polman, C. H.,
Lassmann, H.,
and Ravid, R.
(1995)
Nature
375,
798-801[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Gopal-Srivastava, R.,
Cvekl, A.,
and Piatigorsky, J.
(1996)
J. Biol. Chem.
271,
23029-23036[Abstract/Free Full Text]
|
| 15.
|
Gopal-Srivastava, R.,
Cvekl, A.,
and Piatigorsky, J.
(1998)
J. Biol. Chem.
273,
17954-17961[Abstract/Free Full Text]
|
| 16.
|
Gopal-Srivastava, R.,
Kays, W. T.,
and Piatigorsky, J.
(2000)
Mech. Dev.
92,
125-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Gopal-Srivastava, R.,
and Piatigorsky, J.
(1994)
Nucleic Acids Res.
22,
1281-1286[Abstract/Free Full Text]
|
| 18.
|
Dubin, R. A.,
Gopal-Srivastava, R.,
Wawrousek, E. F.,
and Piatigorsky, J.
(1991)
Mol. Cell. Biol.
11,
4340-4349[Abstract/Free Full Text]
|
| 19.
|
Gopal-Srivastava, R.,
Haynes, J. I.,
and Piatigorsky, J.
(1995)
Mol. Cell. Biol.
15,
7081-7090[Abstract]
|
| 20.
|
Gopal-Srivastava, R.,
and Piatigorsky, J.
(1993)
Mol. Cell. Biol.
13,
7144-7152[Abstract/Free Full Text]
|
| 21.
|
Iwaki, A.,
Nagano, T.,
Nakagawa, M.,
Iwaki, T.,
and Fukumaki, Y.
(1997)
Genomics
45,
386-394[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Suzuki, A.,
Sugiyama, Y.,
Hayashi, Y.,
Nyu-i, N.,
Yoshida, M.,
Nonaka, I.,
Ishiura, S.,
Arahata, K.,
and Ohno, S.
(1998)
J. Cell Biol.
140,
1113-1124[Abstract/Free Full Text]
|
| 23.
|
Brady, J. P.,
Garland, D. L.,
Green, D. E.,
Tamm, E. R.,
Giblin, F. J.,
and Wawrousek, E. F.
(2001)
Investig. Ophthalmol. Vis. Sci.
42,
2924-2934[Abstract/Free Full Text]
|
| 24.
|
Adachi, N.,
and Lieber, M. R.
(2002)
Cell
109,
807-809[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Higuchi, R.
(1990)
in
PCR Protocols: A Guide to Methods and Applications
(Innis, A.
, Gelfand, D. H.
, Sninsky, J. J.
, and White, T. J., eds)
, pp. 177-183, Academic Press, Inc., San Diego, CA
|
| 26.
|
Yamada, T.,
Nakamura, T.,
Westphal, H.,
and Russell, P.
(1990)
Curr. Eye Res.
9,
31-37[Medline]
[Order article via Infotrieve]
|
| 27.
|
Reddan, J. R.,
Chepelinsky, A. B.,
Dziedzic, D. C.,
Piatigorsky, J.,
and Goldenberg, E. M.
(1986)
Differentiation
33,
168-174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Blau, H. M.,
Chiu, C. P.,
and Webster, C.
(1983)
Cell
32,
1171-1180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Eustice, D. C.,
Feldman, P. A.,
Colberg-Poley, A. M.,
Buckery, R. M.,
and Neubauer, R. H.
(1991)
BioTechniques
11,
739-743[Medline]
[Order article via Infotrieve]
|
| 30.
|
Wawrousek, E. F.,
Chepelinsky, A. B.,
McDermott, J. B.,
and Piatigorsky, J.
(1990)
Dev. Biol.
137,
68-76[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Connelly, M. A.,
Zhang, H.,
Kieleczawa, J.,
and Anderson, C. W.
(1998)
Genomics
47,
71-83[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Burbelo, P. D.,
Martin, G. R.,
and Yamada, Y.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
9679-9682[Abstract/Free Full Text]
|
| 33.
|
Nickol, J. M.,
and Felsenfeld, G.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2548-2552[Abstract/Free Full Text]
|
| 34.
|
Duncan, M. K.,
Haynes, J. I.,
and Piatigorsky, J.
(1995)
Gene (Amst.)
162,
189-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Angulo, A.,
Kerry, D.,
Huang, H.,
Borst, E. M.,
Razinsky, A., Wu, J.,
Hobom, U.,
Messerle, M.,
and Ghazal, P.
(2000)
J. Virol.
74,
2826-2839[Abstract/Free Full Text]
|
| 36.
|
Jonsson, J. J.,
Converse, A.,
and McIvor, R. S.
(1994)
Gene (Amst.)
140,
187-193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Nolan, E. M.,
Cheung, T. C.,
Burton, D. W.,
and Deftos, L. J.
(1996)
Mol. Cell. Endocrinol.
124,
51-62[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Surinya, K. H.,
Cox, T. C.,
and May, B. K.
(1998)
J. Biol. Chem.
273,
16798-16809[Abstract/Free Full Text]
|
| 39.
|
Gemel, J.,
Jacobsen, C.,
and MacArthur, C. A.
(1999)
J. Biol. Chem.
274,
6020-6026[Abstract/Free Full Text]
|
| 40.
|
Coughlin, B. C.,
Teixeira, S. M.,
Kirchhoff, L. V.,
and Donelson, J. E.
(2000)
J. Biol. Chem.
275,
12051-12060[Abstract/Free Full Text]
|
| 41.
|
Wei, W.,
and Brennan, M. D.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
14518-14523[Abstract/Free Full Text]
|
| 42.
|
Nishimura, S.,
Takahashi, S.,
Kuroha, T.,
Suwabe, N.,
Nagasawa, T.,
Trainor, C.,
and Yamamoto, M.
(2000)
Mol. Cell. Biol.
20,
713-723[Abstract/Free Full Text]
|
| 43.
|
Tanimoto, K.,
Liu, Q.,
Bungert, J.,
and Engel, J. D.
(1999)
Nature
398,
344-348[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Ohtsuki, S.,
Levine, M.,
and Cai, H. N.
(1998)
Genes Dev.
12,
547-556[Abstract/Free Full Text]
|
| 45.
|
Choi, O. R.,
and Engel, J. D.
(1988)
Cell
55,
17-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Foley, K. P.,
and Engel, J. D.
(1992)
Genes Dev.
6,
730-744[Abstract/Free Full Text]
|
| 47.
|
Herault, Y.,
Fraudeau, N.,
Zakany, J.,
and Duboule, D.
(1997)
Development
124,
3493-3500[Abstract]
|
| 48.
|
Sharpe, J.,
Nonchev, S.,
Gould, A.,
Whiting, J.,
and Krumlauf, R.
(1998)
EMBO J.
17,
1788-1798[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Butler, J. E.,
and Kadonaga, J. T.
(2001)
Genes Dev.
15,
2515-2519[Abstract/Free Full Text]
|
| 50.
|
Kutach, A. K.,
and Kadonaga, J. T.
(2000)
Mol. Cell. Biol.
20,
4754-4764[Abstract/Free Full Text]
|
| 51.
|
Burke, T. W.,
and Kadonaga, J. T.
(1997)
Genes Dev.
11,
3020-3031[Abstract/Free Full Text]
|
| 52.
|
Smale, S. T.
(2001)
Genes Dev.
15,
2503-2508[Free Full Text]
|
| 53.
|
West, A. G.,
Gaszner, M.,
and Felsenfeld, G.
(2002)
Genes Dev.
16,
271-288[Free Full Text]
|
| 54.
|
Bell, A. C.,
West, A. G.,
and Felsenfeld, G.
(2001)
Science
291,
447-450[Abstract/Free Full Text]
|
| 55.
|
Ohlsson, R.,
Renkawitz, R.,
and Lobanenkov, V.
(2001)
Trends Genet.
17,
520-527[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Hough, R. B.,
Avivi, A.,
Davis, J.,
Joel, A.,
Nevo, E.,
and Piatigorsky, J.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
8145-8150[Abstract/Free Full Text]
|
| 57.
|
Hayashi, S.,
Goto, K.,
Okada, T. S.,
and Kondoh, H.
(1987)
Genes Dev.
1,
818-828[Abstract/Free Full Text]
|
| 58.
|
Scohy, S.,
Gabant, P.,
Szpirer, C.,
and Szpirer, J.
(2000)
Nucleic Acids Res.
28,
3743-3751[Abstract/Free Full Text]
|
| 59.
|
Mizumoto, Y.,
Kimura, T.,
and Ivell, R.
(1997)
Mol. Cell. Endocrinol.
135,
129-138[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Zhang, X.,
Xing, G.,
Fraizer, G. C.,
and Saunders, G. F.
(1997)
J. Biol. Chem.
272,
29272-29280[Abstract/Free Full Text]
|
| 61.
|
Parmacek, M. S., Ip, H. S.,
Jung, F.,
Shen, T.,
Martin, J. F.,
Vora, A. J.,
Olson, E. N.,
and Leiden, J. M.
(1994)
Mol. Cell. Biol.
14,
1870-1885[Abstract/Free Full Text]
|
| 62.
|
Kappe, G.,
Verschuure, P.,
Philipsen, R. L.,
Staalduinen, A. A.,
Van de Boogaart, P.,
Boelens, W. C.,
and de Jong, W. W.
(2001)
Biochim. Biophys. Acta
1520,
1-6B[Medline]
[Order article via Infotrieve]. P.
|
| 63.
|
de Jong, W. W.,
Caspers, G. J.,
and Leunissen, J. A.
(1998)
Int. J. Biol. Macromol.
22,
151-162[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Whittaker, M. S. Glassy, N. Gude, M. A. Sussman, R. A. Gottlieb, and C. C. Glembotski
Kinetics of the translocation and phosphorylation of {alpha}B-crystallin in mouse heart mitochondria during ex vivo ischemia
Am J Physiol Heart Circ Physiol,
May 1, 2009;
296(5):
H1633 - H1642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. J. Benjamin, Y. Guo, S. Srinivasan, S. Boudina, R. P. Taylor, N. S. Rajasekaran, R. Gottlieb, E. F. Wawrousek, E. D. Abel, and R. Bolli
CRYAB and HSPB2 deficiency alters cardiac metabolism and paradoxically confers protection against myocardial ischemia in aging mice
Am J Physiol Heart Circ Physiol,
November 1, 2007;
293(5):
H3201 - H3209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, R. B. Hough, and J. Piatigorsky
Tissue-specific activity of the blind mole rat and the two nucleotide-mutated mouse {alpha}B-crystallin promoter in transgenic mice
PNAS,
February 20, 2007;
104(8):
2608 - 2613.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. K. McEwen, A. Woolfe, D. Goode, T. Vavouri, H. Callaway, and G. Elgar
Ancient duplicated conserved noncoding elements in vertebrates: A genomic and functional analysis
Genome Res.,
April 1, 2006;
16(4):
451 - 465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Ijichi, N. Tsujimoto, T. Iwaki, Y. Fukumaki, and A. Iwaki
Distal Sox Binding Elements of the {alpha}B-Crystallin Gene Show Lens Enhancer Activity in Transgenic Mouse Embryos
J. Biochem.,
March 1, 2004;
135(3):
413 - 420.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|